REFERENCES

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.

Edoxaban (Lixiana) [Internet].

Show details

Contents

< Prev Next >

REFERENCES

1.: Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 2016 Jan 26;133(4):e38–360. [PubMed: 26673558]
2.: Tracking heart disease and stroke in Canada [Internet]. Ottawa (ON): Public Health Agency of Canada; 2009. [cited 2016 Dec 1]. Available from: http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/pdf/cvd-avs-2009-eng.pdf
3.: Wells G, Coyle D, Cameron C, Steiner S, Coyle K, Kelly S, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation [Internet]. Ottawa (ON): CADTH; 2012 Apr 9. [cited 2016 Oct 25]. (CADTH Therapeutic Reviews). Available from: https://www.cadth.ca/sites/default/files/pdf/NOAC_Therapeutic_Review_final_report.pdf [PubMed: 24279001]
4.: Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006186. [PubMed: 17636831]
5.: Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med. 2007;39(5):371–91. [PubMed: 17701479]
6.: Somberg JC. The impact of comorbidities on stroke prophylaxis strategies in atrial fibrillation patients. Am J Ther. 2011 Nov;18(6):510–7. [PubMed: 22072096]
7.: Atrial fibrillation [Internet]. Ottawa (ON): Heart and Stroke Foundation; 2016. [cited 2016 Dec 1]. Available from: http://www.heartandstroke.ca/heart/conditions/atrial-fibrillation
8.: CDR submission: Lixiana (edoxaban): 15 mg, 30 mg and 60 mg film-coated tablets. Company: Daiichi Sankyo [CONFIDENTIAL manufacturer’s submission]. Laval (QC): Servier Canada Inc.; 2016.
9.: Clinical Study Report: DU176b-C-U301. A phase 3, randomized, double-blind, double-dummy, parallel-group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b (Edoxaban) versus Warfarin in subjects with atrial fibrillation, Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation (ENGAGE AF-TIMI 48) [CONFIDENTIAL internal manufacturer’s report]. Edison (NJ): Daiichi Sankyo Pharma Development; 2013 Oct 28.
10.: Giugliano RP, Ruff CT, Braunwald E, Murply SA, Wiviott SD, Halperin JL, et al. Edoxaban versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093–104. [PubMed: 24251359]
11.: Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006 Apr;27(8):949–53. [PubMed: 16527828]
12.: Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370–5. [PubMed: 11343485]
13.: You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest [Internet]. 2012 [cited 2016 Oct 25];141(2 Suppl):e531S–e575S. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278056/pdf/112304.pdf [PMC free article: PMC3278056] [PubMed: 22315271]
14.: Macle L, Cairns J, Leblanc K, Tsang T, Skanes A, Cox JL, et al. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2016 Oct;32(10):1170–85. [PubMed: 27609430]
15.: Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart J. 2016 Aug 27.
16.: Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation. 2016 Jul 5;134(1):24–36. [PubMed: 27358434]
17.: Di Pasquale G, Riva L. Edoxaban in atrial fibrillation: The ENGAGE AF-TIMI 48 trial. G Ital Cardiol. 2014;15(12 Suppl 1):22S–6S.
18.: Eisen A, Giugliano RP, Ruff CT, Nordio F, Gogia HS, Awasty VR, et al. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial. Am Heart J. 2016 Feb;172:144–51. [PubMed: 26856226]
19.: Giugliano RP, Ruff CT, Rost NS, Silverman S, Wiviott SD, Lowe C, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48. Stroke. 2014 Aug;45(8):2372–8. [PubMed: 24947287]
20.: Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, et al. Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial. Am J Med [Internet]. 2016 Aug [cited 2016 Oct 25];129(8):850–7. Available from: http://www.sciencedirect.com/science/article/pii/S0002934316302467 [PubMed: 26994510]
21.: Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc [Internet]. 2016 May [cited 2016 Oct 25];5. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889207 [PMC free article: PMC4889207] [PubMed: 27207971]
22.: Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail. 2016 Sep;18(9):1153–61. [PubMed: 27349698]
23.: Mega JL, Walker JR, Ruff CT, Vandell AG, Nordio F, Deenadayalu N, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015 Jun 6;385(9984):2280–7. [PubMed: 25769357]
24.: O’Donoghue ML, Ruff CT, Giugliano RP, Murphy SA, Grip LT, Mercuri MF, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. Eur Heart J. 2015;36:1470–7. [PubMed: 25687352]
25.: Rost NS, Giugliano RP, Ruff CT, Murphy SA, Crompton AE, Norden AD, et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke. 2016 Aug;47(8):2075–82. [PubMed: 27387994]
26.: Ruff CT, Giugliano RP, Braunwald E, Mercuri M, Curt V, Betcher J, et al. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol [Internet]. 2014 Aug 12 [cited 2016 Oct 25];64(6):576–84. Available from: http://www.sciencedirect.com/science/article/pii/S0735109714028423 [PubMed: 25104527]
27.: Shimada YJ, Yamashita T, Koretsune Y, Kimura T, Abe K, Sasaki S, et al. Effects of regional differences in Asia on efficacy and safety of Edoxaban compared with Warfarin--Insights from the ENGAGE AF-TIMI 48 trial. Circ J. 2015;79(12):2560–7. [PubMed: 26460886]
28.: Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis. J Am Coll Cardiol. 2016 Sep 13;68(11):1169–78. [PubMed: 27609678]
29.: Skjoth F, Larsen TB, Rasmussen LH, Lip GY. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost. 2014 May 5;111(5):981–8. [PubMed: 24577485]
30.: Xu H, Ruff CT, Giugliano RP, Murphy SA, Nordio F, Patel I, et al. Concomitant use of single antiplatelet therapy with Edoxaban or Warfarin in patients with atrial fibrillation: Analysis from the ENGAGE AF-TIMI48 trial. J Am Heart Assoc [Internet]. 2016 Feb 23 [cited 2016 Dec 7];5(2). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802446 [PMC free article: PMC4802446] [PubMed: 26908401]
31.: Yamashita T, Koretsune Y, Yang Y, Chen SA, Chung N, Shimada YJ, et al. Edoxaban vs. Warfarin in East Asian patients with atrial fibrillation-An ENGAGE AF-TIMI 48 subanalysis. Circ J. 2016;80(4):860–9. [PubMed: 26888149]
32.: ^Pr Lixiana^® (edoxaban): 15 mg, 30 mg and 60 mg film-coated tablets [product monograph]. Parsippany (NJ): Daiichi Sankyo, Inc.; 2016 Aug 31.
33.: Bajaj NS, Kalra R, Patel N, Hashim T, Godara H, Ather S, et al. Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials. PLoS ONE [Internet]. 2016 [cited 2016 Nov 11];11(10):e0163608. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051881 [PMC free article: PMC5051881] [PubMed: 27706224]
34.: Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open [Internet]. 2014 [cited 2016 Oct 25];4(6):e004301. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054633 [PMC free article: PMC4054633] [PubMed: 24889848]
35.: Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016 Feb 1;204:88–94. [PubMed: 26655548]
36.: Morimoto T, Crawford B, Wada K, Ueda S. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies. J Cardiol. 2015 Dec;66(6):466–74. [PubMed: 26162944]
37.: Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, et al. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharm [Internet]. 2016 [cited 2016 Oct 25];8:93–107. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986689 [PMC free article: PMC4986689] [PubMed: 27570467]
38.: Tereshchenko LG, Henrikson CA, Cigarroa J, Steinberg JS. Comparative effectiveness of interventions for stroke prevention in atrial fibrillation: a network meta-analysis. J Am Heart Assoc [Internet]. 2016 May [cited 2016 Oct 25];5. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889191 [PMC free article: PMC4889191] [PubMed: 27207998]
39.: Lega JC, Mismetti P, Cucherat M, Fassier T, Bertoletti L, Chapelle C, et al. Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis. J Thromb Haemost. 2013 Jul;11(7):1240–50. [PubMed: 23659614]

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK475914

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. REFERENCES.

Other titles in this collection

CADTH Common Drug Reviews

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

REFERENCES - Edoxaban (Lixiana)
REFERENCES - Edoxaban (Lixiana)
Conjugative relaxosome accessory transposon protein (plasmid) [Salmonella enteri...
Conjugative relaxosome accessory transposon protein (plasmid) [Salmonella enterica subsp. enterica serovar Typhimurium]
gi|1905442734|emb|CAD5311246.1|
Protein
Protein TraQ (plasmid) [Salmonella enterica subsp. enterica serovar Typhimurium]
Protein TraQ (plasmid) [Salmonella enterica subsp. enterica serovar Typhimurium]
gi|1905442736|emb|CAD5311248.1|
Protein
LITERATURE SEARCH STRATEGY - Edoxaban (Lixiana)
LITERATURE SEARCH STRATEGY - Edoxaban (Lixiana)
hypothetical protein STMLT2P22_CBEKMEGD_04682 (plasmid) [Salmonella enterica sub...
hypothetical protein STMLT2P22_CBEKMEGD_04682 (plasmid) [Salmonella enterica subsp. enterica serovar Typhimurium]
gi|1905442724|emb|CAD5311236.1|
Protein

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Edoxaban (Lixiana) [Internet].

REFERENCES

Views

Other titles in this collection

Related information

Recent Activity